stockrow
Friday 6 November 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024.
- Revenue
- +5.52%
- EPS
- +7.69%
- Free cash flow
- −102.0%
- Total debt
- −0.29%
Quarter to September 2026, against a year earlier
2.28
0.15
−6.17%
Follow PACB
Alert me
Pacific Biosciences of California, Inc. (PACB) P/E ratio
Pacific Biosciences of California, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 426× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 216× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 426×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PACB Pacific Biosciences of California, Inc. | n/m |
| CTKB Cytek Biosciences, Inc. compare | n/m |
| BBNX Beta Bionics, Inc. compare | n/m |
| AHCO AdaptHealth Corp. compare | n/m |
| QDEL QuidelOrtho Corporation compare | n/m |
| KIDS OrthoPediatrics Corp. compare | n/m |
| INMD InMode Ltd. compare | 10.7× |
| BVS Bioventus Inc. compare | 12.3× |
| VREX VAREX IMAGING compare | 34.8× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)